ArticleHeliyon2023
Antiparkinsonian medication masks motor signal progression in de novo patients.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2025Pooled it
- Tracking the longitudinal progression of Bradykinesia in Parkinson's disease from videos using VisionMD.Journal of Parkinson's disease · 2026Article
- Digital Technologies for Symptom Monitoring in Parkinson Disease.Current neurology and neuroscience reports · 2026Review
- Toward future diagnostics of Parkinson's disease: a perspective on multimodal motor assessment and personalized digital twins.Frontiers in aging neuroscience · 2026Article
- Digital gait biomarkers in Parkinson's disease: susceptibility/risk, progression, response to exercise, and prognosis.NPJ Parkinson's disease · 2025Review
- Predicting future fallers in Parkinson's disease using kinematic data over a period of 5 years.NPJ digital medicine · 2024Article
- Improved measurement of disease progression in people living with early Parkinson's disease using digital health technologies.Communications medicine · 2024Article
- A novel machine learning based framework for developing composite digital biomarkers of disease progression.Frontiers in digital health · 2024Article
- Identification of motor progression in Parkinson's disease using wearable sensors and machine learning.NPJ Parkinson's disease · 2023Article
- Medication only improves limb movements while deep brain stimulation improves eye and limb movements during visually-guided reaching in Parkinson's disease.Frontiers in human neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients not yet receiving medication provide insight to drug-naïve early physiology of Parkinson's Disease (PD). Wearable sensors can measure changes in motor features before and after introduction of antiparkinsonian medication. We aimed to identify features of upper limb bradykinesia, postural stability, and gait that measurably progress in de novo PD patients prior to the start of medication, and determine whether these features remain sensitive to progression in the period after commencement of antiparkinsonian medication. Upper limb motion was measured using an inertial sensor worn on a finger, while postural stability and gait were recorded using an array of six wearable sensors. Patients were tested over nine visits at three monthly intervals. The timepoint of start of medication was noted. Three upper limb bradykinetic features (finger tapping speed, pronation supination speed, and pronation supination amplitude) and three gait features (gait speed, arm range of motion, duration of stance phase) were found to progress in unmedicated early-stage PD patients. In all features, progression was masked after the start of medication. Commencing antiparkinsonian medication is known to lead to masking of progression signals in clinical measures in de novo PD patients. In this study, we show that this effect is also observed with digital measures of bradykinetic and gait motor features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.